Tempus AI (NASDAQ:TEM) EVP Andrew Polovin Sells 22,148 Shares

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 22,148 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $1,098,762.28. Following the completion of the sale, the executive vice president directly owned 146,067 shares of the company’s stock, valued at $7,246,383.87. The trade was a 13.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Polovin sold 7,927 shares of Tempus AI stock. The shares were sold at an average price of $56.00, for a total transaction of $443,912.00.

Tempus AI Stock Up 8.8%

Shares of Tempus AI stock opened at $66.65 on Friday. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The company’s fifty day simple moving average is $52.44 and its two-hundred day simple moving average is $51.21. The company has a market cap of $12.03 billion, a P/E ratio of -46.28 and a beta of 3.58. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same period last year, the company posted ($0.22) EPS. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. Research analysts anticipate that Tempus AI, Inc. will post -1.38 EPS for the current year.

Institutional Trading of Tempus AI

A number of institutional investors and hedge funds have recently bought and sold shares of TEM. Victory Capital Management Inc. lifted its stake in shares of Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after buying an additional 162 shares in the last quarter. Truist Financial Corp grew its holdings in shares of Tempus AI by 5.8% during the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after buying an additional 194 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Tempus AI by 3.5% during the fourth quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock valued at $377,000 after acquiring an additional 219 shares in the last quarter. SeaCrest Wealth Management LLC increased its position in shares of Tempus AI by 3.7% during the third quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock valued at $524,000 after acquiring an additional 229 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in Tempus AI by 29.4% in the 4th quarter. Geneos Wealth Management Inc. now owns 1,100 shares of the company’s stock worth $65,000 after acquiring an additional 250 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on TEM. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a research note on Friday, July 31st. Guggenheim raised their price objective on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Freedom Capital raised Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. BTIG Research boosted their target price on shares of Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a report on Thursday. Finally, Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Tempus AI currently has a consensus rating of “Hold” and a consensus target price of $65.69.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and reaffirmed a “Buy” rating. The new target implies approximately 20% upside from the referenced price and provides a direct catalyst for buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investors are increasingly focused on Tempus AI’s approximately $1.5 billion all-stock acquisition of Personalis. Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Reported progress involving Moderna and Merck in cancer vaccines has improved sentiment toward genomic-data providers and made Tempus’ Personalis strategy appear more timely. The benefit to TEM is indirect, but the developments support the company’s oncology growth narrative. Tempus AI and cancer vaccine developments
• Positive Sentiment: Call-option volume reached 40,671 contracts, about 57% above typical activity, signaling bullish speculation and potentially amplifying momentum.
• Neutral Sentiment: TEM’s move above key moving averages has been described as a possible short squeeze. This can support further gains, but it also raises volatility and reversal risk. Tempus AI technical rally
• Negative Sentiment: Several executives sold shares, including CEO Eric Lefkofsky, CFO James William Rogers and EVP Andrew Polovin. The sales totaled substantial amounts and reduced their holdings, which can concern investors. However, the transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.